ライフサイエンス研究メディア

バイオマーケットjpはバイオ・ライフサイエンス研究に役立つ情報を発信するWebメディアです

A database of travel-related behaviors and attitudes before, during, and after COVID-19 in the United States


Posted: 2021-09-24 19:00:00
The COVID-19 pandemic has impacted billions of people around the world. To capture some of these impacts in the United States, we are conducting a nationwide longitudinal survey collecting information about activity and travel-related behaviors and attitudes before, during, and after the COVID-19 pandemic. The survey questions cover a wide range of topics including commuting, daily travel, air travel, working from home, online learning, shopping, and risk perception, along with attitudinal, socioeconomic, and demographic information. The survey is deployed over multiple waves to the same respondents to monitor how behaviors and attitudes evolve over time. Version 1.0 of the survey contains 8,723 responses that are publicly available. This article details the methodology adopted for the collection, cleaning, and processing of the data. In addition, the data are weighted to be representative of national and regional demographics. This survey dataset can aid researchers, policymakers, businesses, and government agencies in understanding both the extent of behavioral shifts and the likelihood that changes in behaviors will persist after COVID-19.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
4月 21, 2020 バイオアソシエイツ

Gilead社は調査中の化合物RemdesivirのCOVID-19に対する進捗を更新

Gilead Sciences社は、世界の保健当局と緊密に協力して、調査用化合物「Remdesivir(レムデシビル)」(画像)の実験的使用を通じ、新型コロナウイルス( COVID-19 )に対応していることを報告した。米国食品医薬品局(FDA)、疾病対策センター(CDC)、保健福祉省(DHHS)、米国立アレルギー感染症研究所(NIAID)、国防総省(DoD)- CBRN Medical、中国CDCおよび国家医療製品管理局(NMPA)、世界保健機関(WHO)、そして個々の研究者と臨床医と共同して、Gilead…

ゲスト 821人 と メンバー 6人 がオンラインです